.Attribute Medication, Posted online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized period 3b/4 DESTINY-Breast12 study, trastuzumab deruxtecan (T-DXd) procedure of clients with HER2+ enhanced breast cancer and also energetic or secure human brain metastases showed steady intracranial activity and wide spread efficacy of T-DXd.